Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Recurrence 1Pancreatic Neoplasms 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × 1-methyltryptophan × Clear all
NCT02460367 2022-04-06

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Lumos Pharma

Phase 1 Terminated
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

NCT00739609 2020-05-28

D-1MT

Lumos Pharma

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡